Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Особенности фармакологического действия и применения дипиридамола в профилактике и лечении вирусных инфекций
Особенности фармакологического действия и применения дипиридамола в профилактике и лечении вирусных инфекций
Карева Е.Н. Особенности фармакологического действия и применения дипиридамола в профилактике и лечении вирусных инфекций. Consilium Medicum. 2016; 18 (12): 80–87. DOI: 10.26442/2075-1753_2016.12.80-87
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В обзоре приведены современные сведения о молекулярных механизмах антиагрегантного, сосудорасширяющего, ангиопротекторного, противофибротического и иммуномодулирующего действия дипиридамола. Представлены данные отечественных исследований, посвященные испытанию эффективности и безопасности применения дипиридамола (Курантила) в профилактике острых респираторных вирусных инфекций и лечении рецидивирующих стрессиндуцированных оппортунистических инфекционных заболеваний, в которых показано, что дипиридамол является эффективным препаратом комплексного действия с хорошим профилем безопасности и способностью оказывать положительное действие на сосуды при метаболических нарушениях у пациентов с отягощенным анамнезом, позволяет проводить эффективную профилактику острых респираторных вирусных инфекций у пациентов групп высокого риска.
Ключевые слова: дипиридамол, молекулярные механизмы действия, профилактика и лечение острых респираторных вирусных инфекций, органопротекторное действие, пациенты группы высокого риска.
Ключевые слова: дипиридамол, молекулярные механизмы действия, профилактика и лечение острых респираторных вирусных инфекций, органопротекторное действие, пациенты группы высокого риска.
________________________________________________
The review presents recent data on the molecular mechanisms of antiplatelet, vasodilatory, angioprotective, antifibrotic and immunomodulatory effects of dipyridamole. The data of national studies on testing the effectiveness and safety of dipyridamole (Curantyl) in the prevention of acute respiratory viral infections and in the treatment of recurrent stress-induced opportunistic infections, which have shown that dipyridamole is an effective drug complex action with a good safety profile and the ability to have a positive effect on vessels in metabolic disorders in patients with a history of history, enables effective prevention of acute respiratory viral infections in patients at high risk.
Key words: dipyridamole, molecular mechanisms of action, prevention and treatment of acute respiratory viral infections, organ-action, high-risk patients.
Key words: dipyridamole, molecular mechanisms of action, prevention and treatment of acute respiratory viral infections, organ-action, high-risk patients.
Полный текст
Список литературы
1. Ahn HS, Crim W, Romano M et al. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol 1989; 38: 3331–9.
2. Aktas B, Utz A, Hoenig-Liedl P et al. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke 2003; 34 (3): 764–9.
3. Balakumar P, Nyoa YH, Renushiaa R et al. Classical and pleiotropic actions of dipyridamole: Not enough light toilluminate the dark tunnel? Pharmacol Res 2014; 87: 144–50. DOI: 10.1016/j.phrs.2014.05.008.
4. Balakumar P, Varatharajan R, Nyo YH et al. Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats. Pharmacol Res 2014; 90: 36–47. DOI: 10.1016/j.phrs.2014.08.008.
5. Barzegar A. Proton-Coupled Electron-Transfer Mechanism for the Radical Scavenging Activity of Cardiovascular Drug Dipyridamole. PLoS ONE 2012; 7 (6): e39660. DOI: 10.1371/journal.pone.0039660
6. Ciacciarelli M, Zerbinati C, Violi F, Iuliano L. Dipyridamole: a drug with unrecognized antioxidant activity. Curr Top Med Chem 2015; 15 (9): 822–9.
7. Costantini V, Talpacci A, Bastiano ML et al. Increased prostacyclin production from human veins by dipyridamole: an in vitro and ex vivo study. Biomed Biochim Acta 1990; 49: 263–71.
8. Della Corte G, Galasso F et al. Combinazione interferone a-2a per via sistemica e diatermocoagulazione versus semplice diatermocoagulazione nel trattamento dei condilomi acuminati. G Ital Dermatol Venereol 1992; 127: 309–13.
9. Ernens I, Léonard F, Vausort M et al. Adenosine up-regulates vascular endothelial growth factor in human macrophages. Biochem Biophys Res Commun 2010; 392 (3): 351–6. DOI: 10.1016/j.bbrc.2010.01.023.
10. Ferrandon P, Barcelo B, Perche JC, Schoffs AR. Effects of dipyridamole, soluflazine and related molecules on adenosine uptake and metabolism by isolated human red blood cells. Fundam Clin Pharmacol 1994; 8: 446–52.
11. Francis SH, Blount MA, Corbin JD. Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions. Physiol Rev 2011; 91: 651–90. DOI: 10.1152/physrev.00030.2010.
12. Galabov AS, Mastikova M. Acta Virol 1982; 38: 137–47.
13. Galabov AS, Mastikova M. Dipyridamole induces interferon in man. Biomed Pharmacother 1984; 38: 412–3.
14. Galabov AS, Mastikova M. Interferon-inducing activity of dipyridamole in mice. Acta Virologica Prague 1983; 27: 356–8.
15. Geiger J, Nolte C, Walter U. Regulation of calcium mobilization and entry in human platelets by endothelium-derived factors. Am J Physiol 1994; 267: C236–C244.
16. Gresele P, Arnout J, Deckmyn H, Vermylen J. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb Haemost 1986; 55: 12–8.
17. Goda AE, Yoshida T, Horinaka M et al. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene 2008; 27: 3435–45. DOI: 10.1038/sj.onc.1211008.
18. Guo Sh, Stins M, Ning MM, Lo EH. Amelioration of Inflammation and Cytotoxicity by Dipyridamole in Brain Endothelial Cells. Cerebrovasc Dis 2010; 30: 290–6. DOI: 10.1159/000319072.
19. Hsieh MS, Zhong WB, Yu SC et al. Dipyridamole suppresseshigh glucose-induced osteopontin secretion and mRNA expression in rat aorticsmooth muscle cells. Circ J 2010; 74: 1242–50.
20. Hung K-Y, Chen C-T, Yen C-J et al. Dipyridamole inhibits PDGF-stimulated human peritoneal mesothelial cell proliferation. Kidney International 2001; 60: 872–81.
21. Jefferson TO, Tyrrel D. Antivirals for the common cold. The Cochrane Database of Systematic Reviews, Issue. Art. No.: CD002743. DOI: 10.1002/14651858. CD002743, 2004.
22. Kam A, Razmovski-Naumovski V, Xian Zhoub et al. Nucleoside Transport Inhibition by Dipyridamole Prevents Angiogenesis Impairment by Homocysteine and Adenosine. J Pharm Pharm Sci 2015; 18 (5): 871–81.
23. Kim H-H, James K. Liao Translational Therapeutics of Dipyridamole. Arterioscler Thromb Vasc Biol 2008; 28: s39–s42.
24. Kim JA, Tran ND, Zhou W, Fisher M. Dipyridamole enhances tissue plasminogen activator release by brain capillary endothelial cells. Thromb Res 2005; 115 (5): 435–8.
25. Kyttaris VC, Zhang Zh, Kampagianni O, Tsokos GC. Calcium Signaling in Systemic Lupus Erythematosus T Cells A Treatment Target. Arthritis Rheum 2011; 63 (7): 2058–66. DOI: 10.1002/art.30353.
26. Lana D, Melani A, Pugliese AM et al. The neuron-astrocyte-microglia triad in a rat model of chronic cerebral hypoperfusion: protective effect of dipyridamole. Front Aging Neurosci 2014; 27 November. http://dx.doi.org/10.3389/fnagi.2014.00322
27. Lenz TL, Hilleman DE. Aggrenox: a fixed-dose combination of aspirin and dipyridamole. Ann Pharmacother 2000; 34 (11): 1283–90.
28. Massaro M, Scoditti E, Carluccio MA et al. Dipyridamole decreases inflammatory metalloproteinase-9 expressionand release by human monocytes. Thromb Haemost 2013; 109: 280–9.
29. Pattillo ChB, Fang K, Terracciano J, Kevil CG. Reperfusion of chronic tissue ischemia: nitrite and dipyridamole regulation of innate immune responses. Ann N Y Acad Sci 2010; 1207: 83–8. DOI: 10.1111/j.1749-6632.2010.05737.
30. Pattillo ChB, Bir SC, Branch BG et al. Dipyridamole Reverses Peripheral Ischemia and Induces Angiogenesis in the Db/Db Diabetic Mouse Hind Limb Model by Decreasing Oxidative Stress. Free Radic Biol Med 2011; 50 (2): 262–9. DOI: 10.1016/j.freeradbiomed.2010.10.714.
31. Saino T, Misaki T, Matsuura M et al. Dipyridamole inhibits intracellular calcium transients in isolated rat arteriole smooth muscle cells. Arch Histol Cytol 2008; 71 (4): 235–47.
32. Schaper W. Dipyridamole, an Underestimated Vascular Protective Drug. Cardiovasc Drugs Ther 2005; 19: 357–63.
33. Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001; 62: 1153–61.
34. Uchakin PN, Surkina ID, Gotovtseva EP et al. J Interferon Res 1992; 12: 124.
35. Wang Ch, Schwab LP, Fan M et al. Chemoprevention Activity of Dipyridamole in the MMTV-PyMT Transgenic Mouse Model of Breast Cancer. Cancer Prev Res (Phila) 2013; 6 (5). DOI: 10.1158/1940-6207.CAPR-12-0345.
36. Wang C, Lin W, Playa H et al. Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4). Biochem Pharmacol 2013; 86: 1531–40.
37. Weyrich AS, Denis MM, Kuhlmann-Eyre JR et al. Dipyridamole Selectively Inhibits Inflammatory Gene Expression in Platelet–Monocyte Aggregates. Circulation 2005; 111: 633–42.
38. Zhuplatov SB, Masaki T, Blumenthal DK, Cheung AK. Mechanism of dipyri-damole’s action in inhibition of venous and arterial smooth muscle cellproliferation. Basic Clin Pharmacol Toxicol 2006; 99: 431–9.
39. Барышникова Г.А. Дипиридамол в общетерапевтической практике. Проблемы женского здоровья. 2007; 2 (1). / Baryshnikova G.A. Dipiridamol v obshcheterapevticheskoi praktike. Problemy zhenskogo zdorov'ia. 2007; 2 (1). [in Russian]
40. Григорян С.С., Поверенный А.М., Ершов Ф.И. Вазодилататоры как индукторы интерферона. Вопр. вирусологии. 1987; 3: 356–7. / Grigorian S.S., Poverennyi A.M., Ershov F.I. Vazodilatatory kak induktory interferona. Vopr. virusologii. 1987; 3: 356–7. [in Russian]
41. Григорян С.С. Индукторы интерферона: действие на интерфероновый статус в норме и при патологии. Автореф. дис. … д-ра мед. наук. М., 1992. / Grigorian S.S. Induktory interferona: deistvie na interferonovyi status v norme i pri patologii. Avtoref. dis. … d-ra med. nauk. М., 1992. [in Russian]
42. Гуревич К.Г., Суркина И.Д., Готовцева Е.П. и др. Дипиридамол в лечении рецидивирующих стресс-индуцированных оппортунистических инфекционных заболеваний. Рус. мед. журн. 2000; 13: 554–6. http://www.rmj.ru/articles/infektsiya/Dipiridamol_v_lechenii_recidiviruyuschih_stress-inducirovannyh... / Gurevich K.G., Surkina I.D., Gotovtseva E.P. i dr. Dipiridamol v lechenii retsidiviruiushchikh stress-indutsirovannykh opportunisticheskikh infektsionnykh zabolevanii. Rus. med. zhurn. 2000; 13: 554–6. http://www.rmj.ru/articles/infektsiya/Dipiridamol_v_lechenii_recidiviruyuschih_stress-inducirovannyh... [in Russian]
43. Ершов Ф.И. В кн.: Система интерферона в норме и при патологии. M., 1996; с. 239. / Ershov F.I. V kn.: Sistema interferona v norme i pri patologii. M., 1996; s. 239. [in Russian]
44. Ершов Ф.И., Григорян С.С. Курантил как средство неспецифической профилактики гриппа и других ОРВИ. Рекомендации для врачей. Петрозаводск: ИнтелТек, 2004. / Ershov F.I., Grigorian S.S. Kurantil kak sredstvo nespetsificheskoi profilaktiki grippa i drugikh ORVI. Rekomendatsii dlia vrachei. Petrozavodsk: IntelTek, 2004. [in Russian]
45. Кузмов К., Галабов А.С., Радова X. и др. Эпидемиологическое испытание профилактической эффективности индуктора интерферона дипиридамола в отношении острых респираторных заболеваний. Журн. микробиологии, эпидемиологии, иммунологии. 1985; 6: 26–30. / Kuzmov K., Galabov A.S., Radova X i dr. Epidemiologicheskoe ispytanie profilakticheskoi effektivnosti induktora interferona dipiridamola v otnoshenii ostrykh respiratornykh zabolevanii. Zhurn. mikrobiologii, epidemiologii, immunologii. 1985; 6: 26–30. [in Russian]
46. Лукьянов С.В., Белоусов Ю.Б. В кн.: Клиническая фармакология курантила (дипиридамола). M., 1998. / Luk'ianov S.V., Belousov Iu.B. V kn.: Klinicheskaia farmakologiia kurantila (dipiridamola). M., 1998. [in Russian]
47. Меерсон Ф.З. В кн.: Адаптация, стресс, профилактика. M., 1981. / Meerson F.Z. V kn.: Adaptatsiia, stress, profilaktika. M., 1981. [in Russian]
48. Слепушкин А.Н., Федорова Г.И. Клиническое применение дипиридамола (Курантила) для профилактики острых респираторных заболеваний. Клин. фармакология и терапия. 2000; 9: 39–41. / Slepushkin A.N., Fedorova G.I. Klinicheskoe primenenie dipiridamola (Kurantila) dlia profilaktiki ostrykh respiratornykh zabolevanii. Klin. farmakologiia i terapiia. 2000; 9: 39–41. [in Russian]
49. Суркина И.Д. Интерферон-индуцирующие эффекты дипиридамола: противовирусные и регуляторные. Терапевт. арх. 2000; 8: 61–4. / Surkina I.D. Interferon-indutsiruiushchie effekty dipiridamola: protivovirusnye i reguliatornye. Terapevt. arkh. 2000; 8: 61–4. [in Russian]
50. Федоровская Е.О., Пелевина И.И., Ершов Ф.И., Григорян С.С. Подавление метастазирования карциномы Льюис у мышей вазодилататором курантилом, индуцирующим интерферон. БЭБиМ. 1989; 1: 83–5. / Fedorovskaia E.O., Pelevina I.I., Ershov F.I., Grigorian S.S. Podavlenie metastazirovaniia kartsinomy L'iuis u myshei vazodilatatorom kurantilom, indutsiruiushchim interferon. BEBiM. 1989; 1: 83–5. [in Russian]
51. Johnston-Cox HA, Ravid K. Adenosine and blood platelets. Purinergic Signalling. 2011; 7: 357–65. DOI: 10.1007/s11302-011-9220-4.
2. Aktas B, Utz A, Hoenig-Liedl P et al. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke 2003; 34 (3): 764–9.
3. Balakumar P, Nyoa YH, Renushiaa R et al. Classical and pleiotropic actions of dipyridamole: Not enough light toilluminate the dark tunnel? Pharmacol Res 2014; 87: 144–50. DOI: 10.1016/j.phrs.2014.05.008.
4. Balakumar P, Varatharajan R, Nyo YH et al. Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats. Pharmacol Res 2014; 90: 36–47. DOI: 10.1016/j.phrs.2014.08.008.
5. Barzegar A. Proton-Coupled Electron-Transfer Mechanism for the Radical Scavenging Activity of Cardiovascular Drug Dipyridamole. PLoS ONE 2012; 7 (6): e39660. DOI: 10.1371/journal.pone.0039660
6. Ciacciarelli M, Zerbinati C, Violi F, Iuliano L. Dipyridamole: a drug with unrecognized antioxidant activity. Curr Top Med Chem 2015; 15 (9): 822–9.
7. Costantini V, Talpacci A, Bastiano ML et al. Increased prostacyclin production from human veins by dipyridamole: an in vitro and ex vivo study. Biomed Biochim Acta 1990; 49: 263–71.
8. Della Corte G, Galasso F et al. Combinazione interferone a-2a per via sistemica e diatermocoagulazione versus semplice diatermocoagulazione nel trattamento dei condilomi acuminati. G Ital Dermatol Venereol 1992; 127: 309–13.
9. Ernens I, Léonard F, Vausort M et al. Adenosine up-regulates vascular endothelial growth factor in human macrophages. Biochem Biophys Res Commun 2010; 392 (3): 351–6. DOI: 10.1016/j.bbrc.2010.01.023.
10. Ferrandon P, Barcelo B, Perche JC, Schoffs AR. Effects of dipyridamole, soluflazine and related molecules on adenosine uptake and metabolism by isolated human red blood cells. Fundam Clin Pharmacol 1994; 8: 446–52.
11. Francis SH, Blount MA, Corbin JD. Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions. Physiol Rev 2011; 91: 651–90. DOI: 10.1152/physrev.00030.2010.
12. Galabov AS, Mastikova M. Acta Virol 1982; 38: 137–47.
13. Galabov AS, Mastikova M. Dipyridamole induces interferon in man. Biomed Pharmacother 1984; 38: 412–3.
14. Galabov AS, Mastikova M. Interferon-inducing activity of dipyridamole in mice. Acta Virologica Prague 1983; 27: 356–8.
15. Geiger J, Nolte C, Walter U. Regulation of calcium mobilization and entry in human platelets by endothelium-derived factors. Am J Physiol 1994; 267: C236–C244.
16. Gresele P, Arnout J, Deckmyn H, Vermylen J. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb Haemost 1986; 55: 12–8.
17. Goda AE, Yoshida T, Horinaka M et al. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene 2008; 27: 3435–45. DOI: 10.1038/sj.onc.1211008.
18. Guo Sh, Stins M, Ning MM, Lo EH. Amelioration of Inflammation and Cytotoxicity by Dipyridamole in Brain Endothelial Cells. Cerebrovasc Dis 2010; 30: 290–6. DOI: 10.1159/000319072.
19. Hsieh MS, Zhong WB, Yu SC et al. Dipyridamole suppresseshigh glucose-induced osteopontin secretion and mRNA expression in rat aorticsmooth muscle cells. Circ J 2010; 74: 1242–50.
20. Hung K-Y, Chen C-T, Yen C-J et al. Dipyridamole inhibits PDGF-stimulated human peritoneal mesothelial cell proliferation. Kidney International 2001; 60: 872–81.
21. Jefferson TO, Tyrrel D. Antivirals for the common cold. The Cochrane Database of Systematic Reviews, Issue. Art. No.: CD002743. DOI: 10.1002/14651858. CD002743, 2004.
22. Kam A, Razmovski-Naumovski V, Xian Zhoub et al. Nucleoside Transport Inhibition by Dipyridamole Prevents Angiogenesis Impairment by Homocysteine and Adenosine. J Pharm Pharm Sci 2015; 18 (5): 871–81.
23. Kim H-H, James K. Liao Translational Therapeutics of Dipyridamole. Arterioscler Thromb Vasc Biol 2008; 28: s39–s42.
24. Kim JA, Tran ND, Zhou W, Fisher M. Dipyridamole enhances tissue plasminogen activator release by brain capillary endothelial cells. Thromb Res 2005; 115 (5): 435–8.
25. Kyttaris VC, Zhang Zh, Kampagianni O, Tsokos GC. Calcium Signaling in Systemic Lupus Erythematosus T Cells A Treatment Target. Arthritis Rheum 2011; 63 (7): 2058–66. DOI: 10.1002/art.30353.
26. Lana D, Melani A, Pugliese AM et al. The neuron-astrocyte-microglia triad in a rat model of chronic cerebral hypoperfusion: protective effect of dipyridamole. Front Aging Neurosci 2014; 27 November. http://dx.doi.org/10.3389/fnagi.2014.00322
27. Lenz TL, Hilleman DE. Aggrenox: a fixed-dose combination of aspirin and dipyridamole. Ann Pharmacother 2000; 34 (11): 1283–90.
28. Massaro M, Scoditti E, Carluccio MA et al. Dipyridamole decreases inflammatory metalloproteinase-9 expressionand release by human monocytes. Thromb Haemost 2013; 109: 280–9.
29. Pattillo ChB, Fang K, Terracciano J, Kevil CG. Reperfusion of chronic tissue ischemia: nitrite and dipyridamole regulation of innate immune responses. Ann N Y Acad Sci 2010; 1207: 83–8. DOI: 10.1111/j.1749-6632.2010.05737.
30. Pattillo ChB, Bir SC, Branch BG et al. Dipyridamole Reverses Peripheral Ischemia and Induces Angiogenesis in the Db/Db Diabetic Mouse Hind Limb Model by Decreasing Oxidative Stress. Free Radic Biol Med 2011; 50 (2): 262–9. DOI: 10.1016/j.freeradbiomed.2010.10.714.
31. Saino T, Misaki T, Matsuura M et al. Dipyridamole inhibits intracellular calcium transients in isolated rat arteriole smooth muscle cells. Arch Histol Cytol 2008; 71 (4): 235–47.
32. Schaper W. Dipyridamole, an Underestimated Vascular Protective Drug. Cardiovasc Drugs Ther 2005; 19: 357–63.
33. Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001; 62: 1153–61.
34. Uchakin PN, Surkina ID, Gotovtseva EP et al. J Interferon Res 1992; 12: 124.
35. Wang Ch, Schwab LP, Fan M et al. Chemoprevention Activity of Dipyridamole in the MMTV-PyMT Transgenic Mouse Model of Breast Cancer. Cancer Prev Res (Phila) 2013; 6 (5). DOI: 10.1158/1940-6207.CAPR-12-0345.
36. Wang C, Lin W, Playa H et al. Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4). Biochem Pharmacol 2013; 86: 1531–40.
37. Weyrich AS, Denis MM, Kuhlmann-Eyre JR et al. Dipyridamole Selectively Inhibits Inflammatory Gene Expression in Platelet–Monocyte Aggregates. Circulation 2005; 111: 633–42.
38. Zhuplatov SB, Masaki T, Blumenthal DK, Cheung AK. Mechanism of dipyri-damole’s action in inhibition of venous and arterial smooth muscle cellproliferation. Basic Clin Pharmacol Toxicol 2006; 99: 431–9.
39. Baryshnikova G.A. Dipiridamol v obshcheterapevticheskoi praktike. Problemy zhenskogo zdorov'ia. 2007; 2 (1). [in Russian]
40. Grigorian S.S., Poverennyi A.M., Ershov F.I. Vazodilatatory kak induktory interferona. Vopr. virusologii. 1987; 3: 356–7. [in Russian]
41. Grigorian S.S. Induktory interferona: deistvie na interferonovyi status v norme i pri patologii. Avtoref. dis. … d-ra med. nauk. М., 1992. [in Russian]
42. Gurevich K.G., Surkina I.D., Gotovtseva E.P. i dr. Dipiridamol v lechenii retsidiviruiushchikh stress-indutsirovannykh opportunisticheskikh infektsionnykh zabolevanii. Rus. med. zhurn. 2000; 13: 554–6. http://www.rmj.ru/articles/infektsiya/Dipiridamol_v_lechenii_recidiviruyuschih_stress-inducirovannyh... [in Russian]
43. Ershov F.I. V kn.: Sistema interferona v norme i pri patologii. M., 1996; s. 239. [in Russian]
44. Ershov F.I., Grigorian S.S. Kurantil kak sredstvo nespetsificheskoi profilaktiki grippa i drugikh ORVI. Rekomendatsii dlia vrachei. Petrozavodsk: IntelTek, 2004. [in Russian]
45. Kuzmov K., Galabov A.S., Radova X i dr. Epidemiologicheskoe ispytanie profilakticheskoi effektivnosti induktora interferona dipiridamola v otnoshenii ostrykh respiratornykh zabolevanii. Zhurn. mikrobiologii, epidemiologii, immunologii. 1985; 6: 26–30. [in Russian]
46. Luk'ianov S.V., Belousov Iu.B. V kn.: Klinicheskaia farmakologiia kurantila (dipiridamola). M., 1998. [in Russian]
47. Meerson F.Z. V kn.: Adaptatsiia, stress, profilaktika. M., 1981. [in Russian]
48. Slepushkin A.N., Fedorova G.I. Klinicheskoe primenenie dipiridamola (Kurantila) dlia profilaktiki ostrykh respiratornykh zabolevanii. Klin. farmakologiia i terapiia. 2000; 9: 39–41. [in Russian]
49. Surkina I.D. Interferon-indutsiruiushchie effekty dipiridamola: protivovirusnye i reguliatornye. Terapevt. arkh. 2000; 8: 61–4. [in Russian]
50. Fedorovskaia E.O., Pelevina I.I., Ershov F.I., Grigorian S.S. Podavlenie metastazirovaniia kartsinomy L'iuis u myshei vazodilatatorom kurantilom, indutsiruiushchim interferon. BEBiM. 1989; 1: 83–5. [in Russian]
51. Johnston-Cox HA, Ravid K. Adenosine and blood platelets. Purinergic Signalling. 2011; 7: 357–65. DOI: 10.1007/s11302-011-9220-4.
2. Aktas B, Utz A, Hoenig-Liedl P et al. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke 2003; 34 (3): 764–9.
3. Balakumar P, Nyoa YH, Renushiaa R et al. Classical and pleiotropic actions of dipyridamole: Not enough light toilluminate the dark tunnel? Pharmacol Res 2014; 87: 144–50. DOI: 10.1016/j.phrs.2014.05.008.
4. Balakumar P, Varatharajan R, Nyo YH et al. Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats. Pharmacol Res 2014; 90: 36–47. DOI: 10.1016/j.phrs.2014.08.008.
5. Barzegar A. Proton-Coupled Electron-Transfer Mechanism for the Radical Scavenging Activity of Cardiovascular Drug Dipyridamole. PLoS ONE 2012; 7 (6): e39660. DOI: 10.1371/journal.pone.0039660
6. Ciacciarelli M, Zerbinati C, Violi F, Iuliano L. Dipyridamole: a drug with unrecognized antioxidant activity. Curr Top Med Chem 2015; 15 (9): 822–9.
7. Costantini V, Talpacci A, Bastiano ML et al. Increased prostacyclin production from human veins by dipyridamole: an in vitro and ex vivo study. Biomed Biochim Acta 1990; 49: 263–71.
8. Della Corte G, Galasso F et al. Combinazione interferone a-2a per via sistemica e diatermocoagulazione versus semplice diatermocoagulazione nel trattamento dei condilomi acuminati. G Ital Dermatol Venereol 1992; 127: 309–13.
9. Ernens I, Léonard F, Vausort M et al. Adenosine up-regulates vascular endothelial growth factor in human macrophages. Biochem Biophys Res Commun 2010; 392 (3): 351–6. DOI: 10.1016/j.bbrc.2010.01.023.
10. Ferrandon P, Barcelo B, Perche JC, Schoffs AR. Effects of dipyridamole, soluflazine and related molecules on adenosine uptake and metabolism by isolated human red blood cells. Fundam Clin Pharmacol 1994; 8: 446–52.
11. Francis SH, Blount MA, Corbin JD. Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions. Physiol Rev 2011; 91: 651–90. DOI: 10.1152/physrev.00030.2010.
12. Galabov AS, Mastikova M. Acta Virol 1982; 38: 137–47.
13. Galabov AS, Mastikova M. Dipyridamole induces interferon in man. Biomed Pharmacother 1984; 38: 412–3.
14. Galabov AS, Mastikova M. Interferon-inducing activity of dipyridamole in mice. Acta Virologica Prague 1983; 27: 356–8.
15. Geiger J, Nolte C, Walter U. Regulation of calcium mobilization and entry in human platelets by endothelium-derived factors. Am J Physiol 1994; 267: C236–C244.
16. Gresele P, Arnout J, Deckmyn H, Vermylen J. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb Haemost 1986; 55: 12–8.
17. Goda AE, Yoshida T, Horinaka M et al. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene 2008; 27: 3435–45. DOI: 10.1038/sj.onc.1211008.
18. Guo Sh, Stins M, Ning MM, Lo EH. Amelioration of Inflammation and Cytotoxicity by Dipyridamole in Brain Endothelial Cells. Cerebrovasc Dis 2010; 30: 290–6. DOI: 10.1159/000319072.
19. Hsieh MS, Zhong WB, Yu SC et al. Dipyridamole suppresseshigh glucose-induced osteopontin secretion and mRNA expression in rat aorticsmooth muscle cells. Circ J 2010; 74: 1242–50.
20. Hung K-Y, Chen C-T, Yen C-J et al. Dipyridamole inhibits PDGF-stimulated human peritoneal mesothelial cell proliferation. Kidney International 2001; 60: 872–81.
21. Jefferson TO, Tyrrel D. Antivirals for the common cold. The Cochrane Database of Systematic Reviews, Issue. Art. No.: CD002743. DOI: 10.1002/14651858. CD002743, 2004.
22. Kam A, Razmovski-Naumovski V, Xian Zhoub et al. Nucleoside Transport Inhibition by Dipyridamole Prevents Angiogenesis Impairment by Homocysteine and Adenosine. J Pharm Pharm Sci 2015; 18 (5): 871–81.
23. Kim H-H, James K. Liao Translational Therapeutics of Dipyridamole. Arterioscler Thromb Vasc Biol 2008; 28: s39–s42.
24. Kim JA, Tran ND, Zhou W, Fisher M. Dipyridamole enhances tissue plasminogen activator release by brain capillary endothelial cells. Thromb Res 2005; 115 (5): 435–8.
25. Kyttaris VC, Zhang Zh, Kampagianni O, Tsokos GC. Calcium Signaling in Systemic Lupus Erythematosus T Cells A Treatment Target. Arthritis Rheum 2011; 63 (7): 2058–66. DOI: 10.1002/art.30353.
26. Lana D, Melani A, Pugliese AM et al. The neuron-astrocyte-microglia triad in a rat model of chronic cerebral hypoperfusion: protective effect of dipyridamole. Front Aging Neurosci 2014; 27 November. http://dx.doi.org/10.3389/fnagi.2014.00322
27. Lenz TL, Hilleman DE. Aggrenox: a fixed-dose combination of aspirin and dipyridamole. Ann Pharmacother 2000; 34 (11): 1283–90.
28. Massaro M, Scoditti E, Carluccio MA et al. Dipyridamole decreases inflammatory metalloproteinase-9 expressionand release by human monocytes. Thromb Haemost 2013; 109: 280–9.
29. Pattillo ChB, Fang K, Terracciano J, Kevil CG. Reperfusion of chronic tissue ischemia: nitrite and dipyridamole regulation of innate immune responses. Ann N Y Acad Sci 2010; 1207: 83–8. DOI: 10.1111/j.1749-6632.2010.05737.
30. Pattillo ChB, Bir SC, Branch BG et al. Dipyridamole Reverses Peripheral Ischemia and Induces Angiogenesis in the Db/Db Diabetic Mouse Hind Limb Model by Decreasing Oxidative Stress. Free Radic Biol Med 2011; 50 (2): 262–9. DOI: 10.1016/j.freeradbiomed.2010.10.714.
31. Saino T, Misaki T, Matsuura M et al. Dipyridamole inhibits intracellular calcium transients in isolated rat arteriole smooth muscle cells. Arch Histol Cytol 2008; 71 (4): 235–47.
32. Schaper W. Dipyridamole, an Underestimated Vascular Protective Drug. Cardiovasc Drugs Ther 2005; 19: 357–63.
33. Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001; 62: 1153–61.
34. Uchakin PN, Surkina ID, Gotovtseva EP et al. J Interferon Res 1992; 12: 124.
35. Wang Ch, Schwab LP, Fan M et al. Chemoprevention Activity of Dipyridamole in the MMTV-PyMT Transgenic Mouse Model of Breast Cancer. Cancer Prev Res (Phila) 2013; 6 (5). DOI: 10.1158/1940-6207.CAPR-12-0345.
36. Wang C, Lin W, Playa H et al. Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4). Biochem Pharmacol 2013; 86: 1531–40.
37. Weyrich AS, Denis MM, Kuhlmann-Eyre JR et al. Dipyridamole Selectively Inhibits Inflammatory Gene Expression in Platelet–Monocyte Aggregates. Circulation 2005; 111: 633–42.
38. Zhuplatov SB, Masaki T, Blumenthal DK, Cheung AK. Mechanism of dipyri-damole’s action in inhibition of venous and arterial smooth muscle cellproliferation. Basic Clin Pharmacol Toxicol 2006; 99: 431–9.
39. Барышникова Г.А. Дипиридамол в общетерапевтической практике. Проблемы женского здоровья. 2007; 2 (1). / Baryshnikova G.A. Dipiridamol v obshcheterapevticheskoi praktike. Problemy zhenskogo zdorov'ia. 2007; 2 (1). [in Russian]
40. Григорян С.С., Поверенный А.М., Ершов Ф.И. Вазодилататоры как индукторы интерферона. Вопр. вирусологии. 1987; 3: 356–7. / Grigorian S.S., Poverennyi A.M., Ershov F.I. Vazodilatatory kak induktory interferona. Vopr. virusologii. 1987; 3: 356–7. [in Russian]
41. Григорян С.С. Индукторы интерферона: действие на интерфероновый статус в норме и при патологии. Автореф. дис. … д-ра мед. наук. М., 1992. / Grigorian S.S. Induktory interferona: deistvie na interferonovyi status v norme i pri patologii. Avtoref. dis. … d-ra med. nauk. М., 1992. [in Russian]
42. Гуревич К.Г., Суркина И.Д., Готовцева Е.П. и др. Дипиридамол в лечении рецидивирующих стресс-индуцированных оппортунистических инфекционных заболеваний. Рус. мед. журн. 2000; 13: 554–6. http://www.rmj.ru/articles/infektsiya/Dipiridamol_v_lechenii_recidiviruyuschih_stress-inducirovannyh... / Gurevich K.G., Surkina I.D., Gotovtseva E.P. i dr. Dipiridamol v lechenii retsidiviruiushchikh stress-indutsirovannykh opportunisticheskikh infektsionnykh zabolevanii. Rus. med. zhurn. 2000; 13: 554–6. http://www.rmj.ru/articles/infektsiya/Dipiridamol_v_lechenii_recidiviruyuschih_stress-inducirovannyh... [in Russian]
43. Ершов Ф.И. В кн.: Система интерферона в норме и при патологии. M., 1996; с. 239. / Ershov F.I. V kn.: Sistema interferona v norme i pri patologii. M., 1996; s. 239. [in Russian]
44. Ершов Ф.И., Григорян С.С. Курантил как средство неспецифической профилактики гриппа и других ОРВИ. Рекомендации для врачей. Петрозаводск: ИнтелТек, 2004. / Ershov F.I., Grigorian S.S. Kurantil kak sredstvo nespetsificheskoi profilaktiki grippa i drugikh ORVI. Rekomendatsii dlia vrachei. Petrozavodsk: IntelTek, 2004. [in Russian]
45. Кузмов К., Галабов А.С., Радова X. и др. Эпидемиологическое испытание профилактической эффективности индуктора интерферона дипиридамола в отношении острых респираторных заболеваний. Журн. микробиологии, эпидемиологии, иммунологии. 1985; 6: 26–30. / Kuzmov K., Galabov A.S., Radova X i dr. Epidemiologicheskoe ispytanie profilakticheskoi effektivnosti induktora interferona dipiridamola v otnoshenii ostrykh respiratornykh zabolevanii. Zhurn. mikrobiologii, epidemiologii, immunologii. 1985; 6: 26–30. [in Russian]
46. Лукьянов С.В., Белоусов Ю.Б. В кн.: Клиническая фармакология курантила (дипиридамола). M., 1998. / Luk'ianov S.V., Belousov Iu.B. V kn.: Klinicheskaia farmakologiia kurantila (dipiridamola). M., 1998. [in Russian]
47. Меерсон Ф.З. В кн.: Адаптация, стресс, профилактика. M., 1981. / Meerson F.Z. V kn.: Adaptatsiia, stress, profilaktika. M., 1981. [in Russian]
48. Слепушкин А.Н., Федорова Г.И. Клиническое применение дипиридамола (Курантила) для профилактики острых респираторных заболеваний. Клин. фармакология и терапия. 2000; 9: 39–41. / Slepushkin A.N., Fedorova G.I. Klinicheskoe primenenie dipiridamola (Kurantila) dlia profilaktiki ostrykh respiratornykh zabolevanii. Klin. farmakologiia i terapiia. 2000; 9: 39–41. [in Russian]
49. Суркина И.Д. Интерферон-индуцирующие эффекты дипиридамола: противовирусные и регуляторные. Терапевт. арх. 2000; 8: 61–4. / Surkina I.D. Interferon-indutsiruiushchie effekty dipiridamola: protivovirusnye i reguliatornye. Terapevt. arkh. 2000; 8: 61–4. [in Russian]
50. Федоровская Е.О., Пелевина И.И., Ершов Ф.И., Григорян С.С. Подавление метастазирования карциномы Льюис у мышей вазодилататором курантилом, индуцирующим интерферон. БЭБиМ. 1989; 1: 83–5. / Fedorovskaia E.O., Pelevina I.I., Ershov F.I., Grigorian S.S. Podavlenie metastazirovaniia kartsinomy L'iuis u myshei vazodilatatorom kurantilom, indutsiruiushchim interferon. BEBiM. 1989; 1: 83–5. [in Russian]
51. Johnston-Cox HA, Ravid K. Adenosine and blood platelets. Purinergic Signalling. 2011; 7: 357–65. DOI: 10.1007/s11302-011-9220-4.
________________________________________________
2. Aktas B, Utz A, Hoenig-Liedl P et al. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke 2003; 34 (3): 764–9.
3. Balakumar P, Nyoa YH, Renushiaa R et al. Classical and pleiotropic actions of dipyridamole: Not enough light toilluminate the dark tunnel? Pharmacol Res 2014; 87: 144–50. DOI: 10.1016/j.phrs.2014.05.008.
4. Balakumar P, Varatharajan R, Nyo YH et al. Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats. Pharmacol Res 2014; 90: 36–47. DOI: 10.1016/j.phrs.2014.08.008.
5. Barzegar A. Proton-Coupled Electron-Transfer Mechanism for the Radical Scavenging Activity of Cardiovascular Drug Dipyridamole. PLoS ONE 2012; 7 (6): e39660. DOI: 10.1371/journal.pone.0039660
6. Ciacciarelli M, Zerbinati C, Violi F, Iuliano L. Dipyridamole: a drug with unrecognized antioxidant activity. Curr Top Med Chem 2015; 15 (9): 822–9.
7. Costantini V, Talpacci A, Bastiano ML et al. Increased prostacyclin production from human veins by dipyridamole: an in vitro and ex vivo study. Biomed Biochim Acta 1990; 49: 263–71.
8. Della Corte G, Galasso F et al. Combinazione interferone a-2a per via sistemica e diatermocoagulazione versus semplice diatermocoagulazione nel trattamento dei condilomi acuminati. G Ital Dermatol Venereol 1992; 127: 309–13.
9. Ernens I, Léonard F, Vausort M et al. Adenosine up-regulates vascular endothelial growth factor in human macrophages. Biochem Biophys Res Commun 2010; 392 (3): 351–6. DOI: 10.1016/j.bbrc.2010.01.023.
10. Ferrandon P, Barcelo B, Perche JC, Schoffs AR. Effects of dipyridamole, soluflazine and related molecules on adenosine uptake and metabolism by isolated human red blood cells. Fundam Clin Pharmacol 1994; 8: 446–52.
11. Francis SH, Blount MA, Corbin JD. Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions. Physiol Rev 2011; 91: 651–90. DOI: 10.1152/physrev.00030.2010.
12. Galabov AS, Mastikova M. Acta Virol 1982; 38: 137–47.
13. Galabov AS, Mastikova M. Dipyridamole induces interferon in man. Biomed Pharmacother 1984; 38: 412–3.
14. Galabov AS, Mastikova M. Interferon-inducing activity of dipyridamole in mice. Acta Virologica Prague 1983; 27: 356–8.
15. Geiger J, Nolte C, Walter U. Regulation of calcium mobilization and entry in human platelets by endothelium-derived factors. Am J Physiol 1994; 267: C236–C244.
16. Gresele P, Arnout J, Deckmyn H, Vermylen J. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb Haemost 1986; 55: 12–8.
17. Goda AE, Yoshida T, Horinaka M et al. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene 2008; 27: 3435–45. DOI: 10.1038/sj.onc.1211008.
18. Guo Sh, Stins M, Ning MM, Lo EH. Amelioration of Inflammation and Cytotoxicity by Dipyridamole in Brain Endothelial Cells. Cerebrovasc Dis 2010; 30: 290–6. DOI: 10.1159/000319072.
19. Hsieh MS, Zhong WB, Yu SC et al. Dipyridamole suppresseshigh glucose-induced osteopontin secretion and mRNA expression in rat aorticsmooth muscle cells. Circ J 2010; 74: 1242–50.
20. Hung K-Y, Chen C-T, Yen C-J et al. Dipyridamole inhibits PDGF-stimulated human peritoneal mesothelial cell proliferation. Kidney International 2001; 60: 872–81.
21. Jefferson TO, Tyrrel D. Antivirals for the common cold. The Cochrane Database of Systematic Reviews, Issue. Art. No.: CD002743. DOI: 10.1002/14651858. CD002743, 2004.
22. Kam A, Razmovski-Naumovski V, Xian Zhoub et al. Nucleoside Transport Inhibition by Dipyridamole Prevents Angiogenesis Impairment by Homocysteine and Adenosine. J Pharm Pharm Sci 2015; 18 (5): 871–81.
23. Kim H-H, James K. Liao Translational Therapeutics of Dipyridamole. Arterioscler Thromb Vasc Biol 2008; 28: s39–s42.
24. Kim JA, Tran ND, Zhou W, Fisher M. Dipyridamole enhances tissue plasminogen activator release by brain capillary endothelial cells. Thromb Res 2005; 115 (5): 435–8.
25. Kyttaris VC, Zhang Zh, Kampagianni O, Tsokos GC. Calcium Signaling in Systemic Lupus Erythematosus T Cells A Treatment Target. Arthritis Rheum 2011; 63 (7): 2058–66. DOI: 10.1002/art.30353.
26. Lana D, Melani A, Pugliese AM et al. The neuron-astrocyte-microglia triad in a rat model of chronic cerebral hypoperfusion: protective effect of dipyridamole. Front Aging Neurosci 2014; 27 November. http://dx.doi.org/10.3389/fnagi.2014.00322
27. Lenz TL, Hilleman DE. Aggrenox: a fixed-dose combination of aspirin and dipyridamole. Ann Pharmacother 2000; 34 (11): 1283–90.
28. Massaro M, Scoditti E, Carluccio MA et al. Dipyridamole decreases inflammatory metalloproteinase-9 expressionand release by human monocytes. Thromb Haemost 2013; 109: 280–9.
29. Pattillo ChB, Fang K, Terracciano J, Kevil CG. Reperfusion of chronic tissue ischemia: nitrite and dipyridamole regulation of innate immune responses. Ann N Y Acad Sci 2010; 1207: 83–8. DOI: 10.1111/j.1749-6632.2010.05737.
30. Pattillo ChB, Bir SC, Branch BG et al. Dipyridamole Reverses Peripheral Ischemia and Induces Angiogenesis in the Db/Db Diabetic Mouse Hind Limb Model by Decreasing Oxidative Stress. Free Radic Biol Med 2011; 50 (2): 262–9. DOI: 10.1016/j.freeradbiomed.2010.10.714.
31. Saino T, Misaki T, Matsuura M et al. Dipyridamole inhibits intracellular calcium transients in isolated rat arteriole smooth muscle cells. Arch Histol Cytol 2008; 71 (4): 235–47.
32. Schaper W. Dipyridamole, an Underestimated Vascular Protective Drug. Cardiovasc Drugs Ther 2005; 19: 357–63.
33. Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001; 62: 1153–61.
34. Uchakin PN, Surkina ID, Gotovtseva EP et al. J Interferon Res 1992; 12: 124.
35. Wang Ch, Schwab LP, Fan M et al. Chemoprevention Activity of Dipyridamole in the MMTV-PyMT Transgenic Mouse Model of Breast Cancer. Cancer Prev Res (Phila) 2013; 6 (5). DOI: 10.1158/1940-6207.CAPR-12-0345.
36. Wang C, Lin W, Playa H et al. Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4). Biochem Pharmacol 2013; 86: 1531–40.
37. Weyrich AS, Denis MM, Kuhlmann-Eyre JR et al. Dipyridamole Selectively Inhibits Inflammatory Gene Expression in Platelet–Monocyte Aggregates. Circulation 2005; 111: 633–42.
38. Zhuplatov SB, Masaki T, Blumenthal DK, Cheung AK. Mechanism of dipyri-damole’s action in inhibition of venous and arterial smooth muscle cellproliferation. Basic Clin Pharmacol Toxicol 2006; 99: 431–9.
39. Baryshnikova G.A. Dipiridamol v obshcheterapevticheskoi praktike. Problemy zhenskogo zdorov'ia. 2007; 2 (1). [in Russian]
40. Grigorian S.S., Poverennyi A.M., Ershov F.I. Vazodilatatory kak induktory interferona. Vopr. virusologii. 1987; 3: 356–7. [in Russian]
41. Grigorian S.S. Induktory interferona: deistvie na interferonovyi status v norme i pri patologii. Avtoref. dis. … d-ra med. nauk. М., 1992. [in Russian]
42. Gurevich K.G., Surkina I.D., Gotovtseva E.P. i dr. Dipiridamol v lechenii retsidiviruiushchikh stress-indutsirovannykh opportunisticheskikh infektsionnykh zabolevanii. Rus. med. zhurn. 2000; 13: 554–6. http://www.rmj.ru/articles/infektsiya/Dipiridamol_v_lechenii_recidiviruyuschih_stress-inducirovannyh... [in Russian]
43. Ershov F.I. V kn.: Sistema interferona v norme i pri patologii. M., 1996; s. 239. [in Russian]
44. Ershov F.I., Grigorian S.S. Kurantil kak sredstvo nespetsificheskoi profilaktiki grippa i drugikh ORVI. Rekomendatsii dlia vrachei. Petrozavodsk: IntelTek, 2004. [in Russian]
45. Kuzmov K., Galabov A.S., Radova X i dr. Epidemiologicheskoe ispytanie profilakticheskoi effektivnosti induktora interferona dipiridamola v otnoshenii ostrykh respiratornykh zabolevanii. Zhurn. mikrobiologii, epidemiologii, immunologii. 1985; 6: 26–30. [in Russian]
46. Luk'ianov S.V., Belousov Iu.B. V kn.: Klinicheskaia farmakologiia kurantila (dipiridamola). M., 1998. [in Russian]
47. Meerson F.Z. V kn.: Adaptatsiia, stress, profilaktika. M., 1981. [in Russian]
48. Slepushkin A.N., Fedorova G.I. Klinicheskoe primenenie dipiridamola (Kurantila) dlia profilaktiki ostrykh respiratornykh zabolevanii. Klin. farmakologiia i terapiia. 2000; 9: 39–41. [in Russian]
49. Surkina I.D. Interferon-indutsiruiushchie effekty dipiridamola: protivovirusnye i reguliatornye. Terapevt. arkh. 2000; 8: 61–4. [in Russian]
50. Fedorovskaia E.O., Pelevina I.I., Ershov F.I., Grigorian S.S. Podavlenie metastazirovaniia kartsinomy L'iuis u myshei vazodilatatorom kurantilom, indutsiruiushchim interferon. BEBiM. 1989; 1: 83–5. [in Russian]
51. Johnston-Cox HA, Ravid K. Adenosine and blood platelets. Purinergic Signalling. 2011; 7: 357–65. DOI: 10.1007/s11302-011-9220-4.
Авторы
Е.Н.Карева
ФГБОУ ВО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1;
ФГБОУ ВО Первый Московский государственный медицинский университет им. И.М.Сеченова. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
elenakareva@mail.ru
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1;
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
elenakareva@mail.ru
ФГБОУ ВО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1;
ФГБОУ ВО Первый Московский государственный медицинский университет им. И.М.Сеченова. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
elenakareva@mail.ru
________________________________________________
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1;
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
elenakareva@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.